Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NCNA with free AI briefings, catalyst countdowns, and dilution alerts.

NCNA · NuCana plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$19.5M Cash on Hand
45.7mo Cash Runway
Follow NCNA by email Get an email when NCNA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NCNA, unsubscribe in one click. Privacy

📣 What NCNA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Fosgemcitabine Palabenamide (NUC-1031) Biliary Tract Cancer Phase 3 · NCT04163900 Terminated
Fosifloxuridine Nafalbenamide (NUC-3373) Colorectal Cancer Phase 1/2 · NCT03428958 Completed
Oxaliplatin Colorectal Cancer Phase 1/2 · NCT03428958 Completed
Epidermal Growth Factor Receptor Tyrosine… Colorectal Cancer Phase 1/2 · NCT03428958 Completed
Irinotecan Hydrochloride Colorectal Cancer Phase 1/2 · NCT03428958 Completed
Fosdesdenosine Sipalabenamide (NUC-7738) Advanced Cancer Phase 1/2 · NCT03829254 Recruiting
Fluorouracil Colorectal Cancer Phase 2 · NCT05678257 Terminated
Irinotecan Colorectal Cancer Phase 2 · NCT05678257 Terminated

Also used in these trials (approved or third-party drugs, not NCNA's own candidates): Cisplatin, Gemcitabine Hydrochloride, Pembrolizumab, Leucovorin, Docetaxel Anhydrous, Bevacizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NCNA holds $19.5M in cash and short-term investments and burns about $1.3M/quarter from operations, an estimated runway of 45.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NCNA files for a raise →

👥 Who Owns NCNA

Insiders 0% Other 5%+ holders 13.6% Institutions (12 holders) 1.9% Public and other holders 84.5%
HolderTypeShares% of sharesAs of
Hugh S. Griffith 5%+ holder (13D) 2,829,961,890 13.60% 2025-06-20
Sofinnova Capital VI FCPR 5%+ holder (13D) 4,987,975 0.02% 2025-02-14
Hugh Griffith
Chief Executive Officer, Director
Insider 1,000,000 0.00% 2026-03-18
Jeffrey D. Bloss
Chief Medical Officer · +109.62M options
Insider 47,136 0.00% 2026-03-18
Martin C.B. Mellish
Director
Insider 28 0.00% 2026-03-18
Elliott M. Levy
Director
Insider 13 0.00% 2026-03-18

Share count 20,809,854,947 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NCNA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NCNA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.